Europe Wearable Injectors Market

Europe Wearable Injectors Market Size (2022 to 2027)

The European wearable injectors market is estimated to be growing at a prominent CAGR of 19.1% during the forecast period and the market size in Europe is predicted to grow from USD 4.49 billion by 2027 from USD 1.87 billion in 2022.

The growing diabetic population in the European region is majorly driving the European wearable injectors market growth. As per the statistics published by the World Health Organization (WHO), an estimated 60 million people have diabetes in the European region. People who have type 2 diabetes require insulin therapy to control their blood sugar levels in the body. These people are using patches like insulin devices named wearable injections to deliver insulin into the body. Mostly these patches are placed on the stomach areas and hands areas.

The growing incidence of needle stick injuries is further fuelling the growth of the wearable injectors market growth in Europe. In addition, the increasing patient population suffering from chronic diseases such as cancer, CVDs, and autoimmune disease leads to an increase in the use of syringes which helps to deliver the drug into the patient's body. During this process, most of the patients and the healthcare provider are affected with needle stick injuries which may lead to severe in some cases, such as injecting people who are suffering from injection diseases such as HIV and other chronic diseases. To avoid these issues, patients use wearable injectors that reduce needle stick injuries and safely deliver the drug into the patient's body.

The growing number of advancements in the development of wearable injectors is contributing to the European wearable injectors market growth. The researchers have been focussing to develop wearable injectors with advanced technologies, such as sensing the patient's activity. If they stop breathing and moving, the injector induces a lifesaving antidot to restore respiration. Furthermore, a growing number of R&D activities around wearable injectors, increasing investments from European governments to develop healthcare infrastructure in the developing countries of the European region, increasing adoption of home-based treatment, and increasing demand for biologics are favoring the growth of the European wearable injectors market.

However, the high costs associated with wearable injectors are majorly restraining the growth of the European wearable injectors market. In addition, lack of awareness, less demand in rural areas, availability of alternative procedures, and less device production are limiting the growth rate of the European market.

This research report on the European wearable injectors market has been segmented and sub-segmented into the following categories:

By Type:

• On-body
• Off-body

The on-body segment is expected to play the leading role of the European wearable injectors market during the forecast period.

By Technology:

• Spring-based
• Motor-driven
• Rotary Pump
• Expanding Battery
• Others

The spring-based segment had the largest share of the European wearable injectors market in 2021.

By Application:

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Others

Based on application, the oncology segment is estimated to hold a leading share of the European wearable injectors market during the forecast period.

By End-use:

• Hospitals
• Clinics
• Home Care
• Others

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European region accounted for a notable share of the worldwide market in 2021 and is expected to hold a considerable share of the global market during the forecast period. The UK market had the major share of the European market in 2021 and is expected to grow promisingly during the forecast period owing to the growing innovation of advanced wearable injectors by the local market participants at affordable prices. In addition, the increasing cancer patient population in the United Kingdom is fuelling the UK market growth. As per the estimates of Macmillan Cancer Support, the cancer patient population in the UK is expected to reach 3.5 million by 2025. People who need a regular supply of the anti-cancer drug in the patient's body use wearable injectors to send minimum dosages at particular intervals to reduce the growth of cancer cells in the body. The UK market growth is further driven by the increasing adoption of advanced medical devices. Owing to the growing health consciousness among people, people are using advanced devices such as wearable injectors to inject drugs into the body without overdosage safely. In addition, increasing awareness programs by healthcare organizations and increasing the advertisement through social media and television about the use of wearable injectors for certain diseases favour the UK market to grow further.

The German wearable injectors market is predicted to hold a considerable share of the European market during the forecast period. The growth of the German market is primarily driven by the increasing number of manufacturing facilities for wearable injectors. In addition, the growing emphasis of key market participants to develop new and advanced wearable injectors is supporting the German market growth.

KEY MARKET PLAYERS:

Companies playing a promising role in the European wearable injectors market profiled in this report are Amgen, Becton, and Dickinson and Company, Medtronic, Valeritas, Inc, Insulet Corporation, Gerresheimer AG (Sensile Medical), Tandem Diabetes Care, SteadyMed Therapeutics, Inc., United Therapeutics Corporation, Sensile Medical AG, Zealand Pharma A/S (Valeritas, Inc.), West Pharmaceutical Services, Inc., SteadyMed Therapeutics, F. Hoffmann-La Roche Ltd, Ypsomed, Johnson & Johnson, Dexcom, Inc., Enable Injections, CeQur SA, Sensile Medicals and Bespak.